• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi promotes Sibold to exec VP of Sanofi Genzyme | Personnel Moves – April 13, 2017

April 17, 2017 By Sarah Faulkner

Bill SiboldSanofi (NYSE:SNY) said at the start of April that it promoted Bill Sibold to exec VP of Sanofi Genzyme, effective July 1, 2017. Sibold succeeds Dr. David Meeker, who is slated to leave the company at the end of June.

Sibold is the head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization. He led the company in preparation for the global launches of Dupilumab and Sarilumab. He joined Sanofi in 2011 as head of the MS business.

“With a strong commitment to serving patients, Sanofi Genzyme has evolved from a rare disease company into a preeminent specialty care business, deeply rooted in science. I am confident in Bill Sibold’s experience and leadership to build on this strong foundation as we chart the next chapter for Sanofi Genzyme, which has become a real growth driver for Sanofi” CEO Olivier Brandicourt said in prepared remarks. “I would also like to thank David Meeker for his tireless dedication to our shared vision for Sanofi Genzyme and his personal passion for the patients we serve, both of which helped make our company the success it is today.”

Sibold has worked at Eli Lilly and also held leadership positions at Biogen, where he guided their U.S. commercial operations in neurology, oncology and rheumatology. He also served as the chief commercial officer of Avanir Pharmaceuticals.

Earlier this month, Sanofi touted real-world clinical data for its Toujeo insulin glargine injection from a new observational study. The data from Deliver 2 showed that patients with Type II diabetes who switched to Toujeo from other basal insulins had significantly lower risk of hypoglycemia without compromising blood sugar control.

 Ocular names interim chief financial officer

Ocular Therapeutix (NSDQ:OCUL) appointed George Migausky as interim chief financial officer after Bradford Smith resigned in February.

“George is a highly regarded financial professional, offering extensive expertise at high-growth private and public life sciences and technology,” president & CEO Amar Sawhney said. “We believe his insights will be invaluable as we continue to undertake pre-commercialization activities for Dextenza in advance of the July 19th PDUFA date and as we make further substantial progress across our additional drug product development programs.”

Read more

 GlucoMe hires Erickson as exec VP, GM of North America biz

GlucoMe named John Erickson as exec VP and general manager of the company’s North American business. He previously served as divisional VP at Abbott, where he was responsible for diabetes products and strategy.

“I am very excited to join GlucoMe, and look forward to helping doctors and patients across the United States better treat diabetes,” Erickson said. “Diabetes management and care are major concerns for tens of millions of American patients, as well as healthcare payers and professionals. GlucoMe’s digital technology and strategic roadmap are opening up an exciting avenue to enable simpler and more effective diabetes care resulting in better outcomes. I look forward to working closely with the entire team as GlucoMe takes its next steps forward.”

Read more

 Mylan taps former SEC commish as chief legal officer

Mylan (NSDQ:MYL) named attorney Daniel Gallagher as chief legal officer, effective April 27. He previously served as SEC commissioner from November 2011 to October 2015.

He joins Mylan from consulting firm Patomak Global Partners.

Read more

 Bausch & Lomb restructure U.S. management team

Bausch & Lomb said that in an effort to restructure its U.S. management team, it has appointed 4 of its employees to new positions.

Senior VP & GM of U.S. consumer healthcare, Joseph Gordon, and senior VP & GM of U.S. pharmaceuticals, Travy Valorie, will have expanded roles to include the U.S. vision care biz and the U.S. surgical biz, respectively.

The company also said that it tapped John Ferris to be VP & GM for U.S. vision care and Chuck Hess will assume the role VP & GM for U.S. surgical.

“These management changes exemplify how we’re continuing to align our resources to be more responsive to the needs of the marketplace by increasing our efficiencies and creating opportunities for potential synergies that will ultimately help drive the company’s overall growth,” Valeant chairman & CEO Joseph Papa said.
Read more

  • Pulmatrix brings on 2 fungal infection experts
  • Alexion names CEO
  • Sherman joins Silicon Therapeutics as CSO
  • Gregory named to Iconic Therapeutics’ board of directors
Pages: Page 1 Page 2

Filed Under: Drug-Device Combinations, Featured, Personnel, Wall Street Beat Tagged With: Abbott Laboratories, bausch&lomb, Biogen Idec, Bristol-Myers Squibb Co., Gerresheimer AG, GlucoMe, Mylan, Ocular Therapeutix, Pulmatrix Inc., Sanofi-Aventis

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS